Vascular endothelial growth factor (VEGF) is a key regulator in angiogenesis. Preclinical and clinical data support the role of VEGF and angiogenesis in renal cell carcinoma (RCC), melanoma (M), and soft tissue sarcoma (STS). The tyrosine kinase inhibitor SU5416 is a potent inhibitor of the VEGF receptors 1 and 2. EXPERIMENTAL DESIGN: We investigated 145 mg/m(2) SU5416 twice weekly in patients with advanced or metastatic RCC, M, and STS. The primary objectives were efficacy and safety. Disease assessments were performed after 4 and 8 weeks of treatment and every 2 months thereafter. Documented stable disease (SD) lasting for > or =3 months was considered an antitumor response. RESULTS: A group of 29 patients was entered in the RCC trial, 20 patients in the M trial, and 31 patients in the STS trial. Response was observed in 6 (1 minor response and 5 SDs) of 24 evaluable patients (25%) in the RCC group, 6 (1 minor response and 5 SDs) of 26 patients (23%) in the STS group, and none of the patients in the M group. Progression-free survival ranged from 7 to 252 days (median 59 days) in the RCC group, from 7 to 260 days (median 60 days) in the STS group, and from 14 to 139 days (median 41 days) in the M group. Toxicities observed were those reported previously for SU5416. CONCLUSION: SU5416 single agent is well tolerated. The antitumor response was low in patients with RCC and STS, whereas no responses were seen in patients with M.

Efficacy and Toxicity of the angiogenesis inhibitor SU 5416 as a single agent in patients with advanced renal cell carcinoma, melanoma and soft tissue sarcoma / Kuenen, Bc; Tabernero, J; Baselga, J; Cavalli, F; Pfanner, E; Conte, Pierfranco; Seeber, S; Madhusudan, S; Deplanque, G; Huisman, H; Scigalla, P; Hoekman, K; Harris, A. L.. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - STAMPA. - 9:(2003), pp. 1648-1655.

Efficacy and Toxicity of the angiogenesis inhibitor SU 5416 as a single agent in patients with advanced renal cell carcinoma, melanoma and soft tissue sarcoma.

CONTE, Pierfranco;
2003

Abstract

Vascular endothelial growth factor (VEGF) is a key regulator in angiogenesis. Preclinical and clinical data support the role of VEGF and angiogenesis in renal cell carcinoma (RCC), melanoma (M), and soft tissue sarcoma (STS). The tyrosine kinase inhibitor SU5416 is a potent inhibitor of the VEGF receptors 1 and 2. EXPERIMENTAL DESIGN: We investigated 145 mg/m(2) SU5416 twice weekly in patients with advanced or metastatic RCC, M, and STS. The primary objectives were efficacy and safety. Disease assessments were performed after 4 and 8 weeks of treatment and every 2 months thereafter. Documented stable disease (SD) lasting for > or =3 months was considered an antitumor response. RESULTS: A group of 29 patients was entered in the RCC trial, 20 patients in the M trial, and 31 patients in the STS trial. Response was observed in 6 (1 minor response and 5 SDs) of 24 evaluable patients (25%) in the RCC group, 6 (1 minor response and 5 SDs) of 26 patients (23%) in the STS group, and none of the patients in the M group. Progression-free survival ranged from 7 to 252 days (median 59 days) in the RCC group, from 7 to 260 days (median 60 days) in the STS group, and from 14 to 139 days (median 41 days) in the M group. Toxicities observed were those reported previously for SU5416. CONCLUSION: SU5416 single agent is well tolerated. The antitumor response was low in patients with RCC and STS, whereas no responses were seen in patients with M.
2003
9
1648
1655
Efficacy and Toxicity of the angiogenesis inhibitor SU 5416 as a single agent in patients with advanced renal cell carcinoma, melanoma and soft tissue sarcoma / Kuenen, Bc; Tabernero, J; Baselga, J; Cavalli, F; Pfanner, E; Conte, Pierfranco; Seeber, S; Madhusudan, S; Deplanque, G; Huisman, H; Scigalla, P; Hoekman, K; Harris, A. L.. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - STAMPA. - 9:(2003), pp. 1648-1655.
Kuenen, Bc; Tabernero, J; Baselga, J; Cavalli, F; Pfanner, E; Conte, Pierfranco; Seeber, S; Madhusudan, S; Deplanque, G; Huisman, H; Scigalla, P; Hoekman, K; Harris, A. L.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/615395
Citazioni
  • ???jsp.display-item.citation.pmc??? 26
  • Scopus 132
  • ???jsp.display-item.citation.isi??? 121
social impact